UPDATE 2-Alnylam's gene-silencing efforts get $2 bln Blackstone backing

Blackstone Group Inc said on Monday it would invest $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost without tapping into currently volatile stock markets for funds.